These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 30101)

  • 1. Indication of an antipsychotic action of the opiate antagonist naloxone.
    Emrich HM; Cording C; Pirée S; Kölling A; von Zerssen D; Herz A
    Pharmakopsychiatr Neuropsychopharmakol; 1977 Sep; 10(5):265-70. PubMed ID: 30101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repeated high dosage naloxone treatment without therapeutic efficacy in schizophrenic patients.
    Naber D; Leibl K
    Pharmacopsychiatria; 1983 Mar; 16(2):43-5. PubMed ID: 6346348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Des-tyrosyl-gamma-endorphin in schizophrenia: a double-blind trial in 13 patients.
    Emrich HM; Zaudig M; Kissling W; Dirlich G; von Zerssen D; Herz A
    Pharmakopsychiatr Neuropsychopharmakol; 1980 Sep; 13(5):290-8. PubMed ID: 7003611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of naloxone in chronic schizophrenia.
    Berger PA; Watson SJ; Akil H; Barchas JD
    Am J Psychiatry; 1981 Jul; 138(7):913-8. PubMed ID: 6266259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected.
    Agid O; Kapur S; Arenovich T; Zipursky RB
    Arch Gen Psychiatry; 2003 Dec; 60(12):1228-35. PubMed ID: 14662555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
    Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
    Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The behavioral toxicity of bromocriptine in patients with psychiatric illness.
    Perovich RM; Lieberman JA; Fleischhacker WW; Alvir J
    J Clin Psychopharmacol; 1989 Dec; 9(6):417-22. PubMed ID: 2574194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.
    Ondo WG; Tintner R; Voung KD; Lai D; Ringholz G
    Mov Disord; 2005 Aug; 20(8):958-63. PubMed ID: 15800937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission.
    Ketter TA; Agid O; Kapur S; Loebel A; Siu CO; Romano SJ
    J Psychiatr Res; 2010 Jan; 44(1):8-14. PubMed ID: 19699488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The treatment of perceptual disturbances in schizophrenia with naloxone hydrochloride.
    Kurland AA; McCabe OL; Hanlon TE; Sullivan D
    Am J Psychiatry; 1977 Dec; 134(12):1408-10. PubMed ID: 335903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Auditory hallucination coping techniques and their relationship to psychotic symptomatology.
    Hayashi N; Igarashi Y; Suda K; Nakagawa S
    Psychiatry Clin Neurosci; 2007 Dec; 61(6):640-5. PubMed ID: 18081625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Introductory words to the exchange of results on the clinical effects of bromperidol. Results of open and double blind research].
    Bures E; Pöldinger W
    Int Pharmacopsychiatry; 1978; 13 Suppl 1():45-52. PubMed ID: 35479
    [No Abstract]   [Full Text] [Related]  

  • 15. Zuclopenthixol: a new generation of antipsychotic drugs. An open clinical trial.
    Matar AM; Abdel-Mawgoud M; Skov S
    J Clin Psychopharmacol; 1990 Aug; 10(4):283-6. PubMed ID: 1981068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma levels of beta-endorphin under chronic neuroleptic treatment in schizophrenic patients: failure of naloxone to counteract curative effects of neuroleptic drugs.
    Emrich HM; Höllt V; Bergmann M; Kissling W; Schmid W; Zerssen DV; Herz A
    Adv Biochem Psychopharmacol; 1980; 22():489-502. PubMed ID: 6104902
    [No Abstract]   [Full Text] [Related]  

  • 17. Intravenous naloxone administration in schizophrenia and affective illness.
    Davis GC; Bunney WE; DeFraites EG; Kleinman JE; van Kammen DP; Post RM; Wyatt RJ
    Science; 1977 Jul; 197(4298):74-7. PubMed ID: 325650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic effect of buprenorphine in schizophrenia.
    Schmauss C; Yassouridis A; Emrich HM
    Am J Psychiatry; 1987 Oct; 144(10):1340-2. PubMed ID: 3310672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Negative naloxone effects in schizophrenic patients.
    Janowsky DS; Segal DS; Abrams A; Bloom F; Guillemin R
    Psychopharmacology (Berl); 1977 Aug; 53(3):295-7. PubMed ID: 19807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of naloxone on the state of patients with endogenous psychoses.
    Lideman RR; Panteleeva GP; Tsutsul'kovskaya MYa ; Vartanyan FE; Belyaev BS
    Neurosci Behav Physiol; 1984; 14(6):471-5. PubMed ID: 6097836
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.